Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Keynote Chat - Investing in Digital Innovation
2017 Saw a wave of investment in Neuro and Neuro startups, while at the same time facing challenges in late stage financing and advancements in CNS disease treatment and drug development. Where is the landscape headed and how might the varying elements impacting the industry play out for those operating in the business of Neuro drug development?
Sit in on an investor/founder origin story and Q&A session with an investor and founder of digital medicine company Sonde Health.
A discussion around not only the difficulties of validation, but how researchers might significantly "move the needle" in a meaningful way through best practices
Sit in on a demo of gadgets and emerging tech with neuro implications
Continue the conversation with tech life sciences as they discuss how innovation in technological modalities can change the landscape for CNS indications
Is there a new paradigm of how we understand Neurodegeneration? What might it mean for future scientific advancement, treatment, and the patient ?
Learn how Wave Life Sciences, a clinical-stage genetics medicines company, is using its chemistry and stereochemistry platform to design nucleic acid therapeutics to address CNS and neuromuscular disorders such as Huntington’s disease, Duchenne muscular dystrophy, amyotrophic lateral sclerosis and frontotemporal dementia. The platform was developed to optimize the pharmacological profile of nucleic acids by maximizing therapeutic effect while minimizing the potential for side effects and safety risks. The company has three programs currently in clinical development.
Explore recent regulatory developments in the space as well as how modalities like gene editing and other emerging treatments might change not only the therapeutic landscape, but the life of the patient
How are companies addressing chronic pain management? Address how safety and efficacy challenges are being addressed in the development of therapeutics in this space
How might the convergence of early stage investment, emerging technology, data utilization and a patient-centric approach shape the trajectory of Neuro therapeutic development?